115
Views
5
CrossRef citations to date
0
Altmetric
Research Article

Characterization of nano oxaliplatin prepared by novel Fat Employing Supercritical Nano System, the FESNS®

, , &
Pages 212-218 | Received 17 Jun 2010, Accepted 09 Oct 2010, Published online: 15 Nov 2010
 

Abstract

Background: Oxaliplatin has long been used for the treatment of colorectal cancer via intra-venous infusion. In order to improve patient compliance, a solid dosage form for oral administration of oxaliplatin was prepared as nano-sized particles.

Method: Nano oxaliplatin was prepared employing Fat Employing Supercritical Nano System (FESNS®) with Supercritical Fluid (SCF) apparatus by using myristyl alcohol as solvent. Morphology of nano oxaliplatin was examined by Scanning Electron Microscopy (SEM), and the particle size and zeta potential were confirmed with Dynamic Light Scattering (DLS). To characterize the nano oxaliplatin particles, solubility rate and in vitro efficacy study (MTS growth inhibition assay) were investigated compared to crude oxaliplatin as reference.

Result: FESNS® provided reproducible nano oxaliplatin with high manufacturing yield (> 95%). SEM images showed that the particle size distribution of nano oxaliplatin ranged between 20 and 400 nm with the medium particle sizes (d50) of about 164 nm determined by DLS. Pertaining to the long-term stability, no recrystallization of the nano oxaliplatin was observed with negative zeta potential in the state of solution. Nano oxaliplatin was completely dissolved within a couple of minutes in pH 4.0 and pH 6.8 buffer solutions while crude oxaliplatin took a couple of hours to go into solution. In case of MTS growth inhibition assay, the average concentration required to inhibit 50% of cell growth (GI50) of nano oxaliplatin was decreased by about 45% in comparison to the crude oxaliplatin.

Conclusion: These results lead us to conclude that nano oxaliplatin would have a great potential for the improvement of efficacy and toxicity in human colorectal cancer treatment compared to the crude oxaliplatin.

Acknowledgments

The authors thank Biosynectics for their technical support and advice for this project.

Declaration of interest

This work was supported by a grant from the Ministry of Health & Welfare of the Korean Government (A084141). The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 523.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.